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Introduction
Ependymomas are relatively rare tumors that arise in the
brain, spinal cord or cauda equina. Spinal ependymomas are
less frequent than intracranial ependymomas. The World
Health Organization (WHO) classified ependymomas into
the following four categories: subependymomas (WHO
grade 1), myxopapillary ependymomas (WHO grade 1),
ependymomas (WHO grade 2) and anaplastic ependymo-
mas (WHO grade 3) [1]. Among these types, a myxopapil-
lary ependymoma is characterized as a slow growing tumor
with preferential manifestation in young adults. Myxopapil-
lary ependymoma is located exclusively in the conus
medullaris or the cauda equina, or film terminale region,
and is rarely found as a multi-focal type. In most myxopap-
illary ependymomas, the histological examination reveals
low mitotic activity that is associated with a low MIB-1
labeling index (LI) [2]. The prognosis is generally favorable
[3]. However, late recurrence, distant metastases and sub-
arachnoid disseminations have been reported [4-6]. We
report an unusual case of multi-focal myxopapillary
ependymoma with extremely high mitotic activity that arose
in the cauda equine. In this case, the mitotic activity of the
tumor was extremely high compared to previously reported
cases [2]. A surgical resection and cranio-spinal radiation
were performed as treatments.
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Ependymomas are uncommon tumors that arise in the brain, spinal cord or cauda equina. Myxopapillary ependymomas is
located exclusively in the conus medullaris or cauda equina, or film terminale region. In most myxopapillary ependymomas,
the histological examination reveals low mitotic activity that is associated with a low MIB-1 labeling index (LI). The prog-
nosis is generally favorable, when the appropriate treatment, including a total resection, is performed. The authors encoun-
tered a 39-year-old man with multifocal type of myxopapillary ependymomas compressing the cauda equina from the L2
to L3 level and L5-S1 level. A subtotal resection of the tumor was carried out. The histological examination revealed
extremely high mitotic activity with a MIB-1 LI of 9.1%. Therefore, cranio-spinal radiation was added after surgery. The
postoperative course was uneventful over the 3.5 year follow-up period.  
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recurrenceCase Report
A 39-year-old man presented with gradually increasing
bilateral buttock pain. He showed intermittent claudication
after walking 500 m. The physical examination revealed
cauda equina syndrome below the L2 level. He had dysuria.
Dejerine signs, postural factor and a positive Kemp sign.
The straight leg raising test was also positive in the bilateral
lower extremities. The deep tendon reflexes in the lower
extremities were diminished, but the reflexes in the upper
extremities were normal. Motor palsy was not evident and
no sensory disturbance was observed in the upper or lower
extremities. The plain radiographs did not reveal any abnor-
malities. Lumbar magnetic resonance imaging (MRI)
demonstrated an intradural tumor compressing the cauda
equina from the L2 to L3 level and L5-S1 level (Fig. 1).
The tumor did not extend beyond the spinal canal (Fig. 2).
The tumor showed low intensity compared to the spinal
cord on the T1-weighted image and high intensity on the
T2-weighted image. Gadolinium enhancement was
observed in the tumor. The tumor mass was not detected in
the cranial, cervical or thoracic levels by MRI.
An en-bloc lumbar laminectomy was carried out and a
total resection of the tumor was performed with an opening
of the dura mater. The tumor showed a round and redish-
gray colored mass covered with a thin membrane. The
tumor was not attached to the dura mater or cauda eqina at
the L2-3 levels. As the tumor was firmly attached to the S2
spinal nerve, it had to be removed piece by piece under a
microscope at the L5-S1 level. After removing the tumor,
the dura mater could be sutured completely. No dural cyst,
due to the leakage of spinal fluid, remained after surgery. 
The gross size of the tumor from the L2-3 level was 4 ×
1.3 cm. Macroscopically, the tumor was soft with a glossy
grayish color and focal hemorrhagic appearance. Histologi-
cally, the tumor from the L2-3 and L5-S1 levels showed
various morphologies with extensive myxoid degeneration.
Most of the tumor cells contained eosinophilic rich cyto-
plasm with bipolar processes. The major part of the tumor
showed reticular arrangement with numerous hyalinized
vessels distributed evenly. The radial arrangement of the
cellular processes against the vascular wall was obvious
(Fig. 3A). Some parts showed marked mucoid degeneration
surrounded by layers of tumor cells (Fig. 3B). The cellular
atypia was not conspicuous and the area of necrosis could
not be identified. Immunohistochemical analysis revealed
the tumor cells to be positive for glial fibrillary acidic pro-
tein (GFAP) and S-100, and negative for keratin, CAM5.2
and epithelial membrane antigen (EMA) (Fig. 3C). A diag-
nosis of myxopapillary ependymoma was made based on
the histological appearance, immunohistochemical profile
and clinical presentation. According to WHO classification,
all myxopapillary ependymoma falls into grade 1. However,
the current case showed relatively frequent mitosis of up to
2/10 hpf and a high MIB-1 LI of 9.1%, which raised the
possibility of a more aggressive tumor (Fig. 3D).
Cranio-spinal radiation therapy was performed 1 month
after surgery. The amount of radiation was 30 Gy for the
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Fig. 1. Enhanced magnetic resonance imaging sagittal
view demonstrating an intradural tumor compressing the
cauda equina from the L2 to L3 level and L5-S1 level.70 / ASJ: Vol. 5, No. 1, 2011
Fig. 2. Enhanced magnetic resonance imaging axial view showing the intra canal tumor at the L2 level (A) and S1
level (B).
Fig. 3. Pathology of the tumor. (A) Tumor cells show radial processes around the vessels (arrows). (B) Areas with
marked mucoid degeneration. Note the mucoid materials surrounding the vessels. (C) Tumor cells are diffusely posi-
tive for glial fibrillary acidic protein. (D) The tumor shows high a MIB-1 labeling index of 9.1%.brain-C2, C3-T10 and T11-S levels, and 10 Gy for the L1-S
levels. Symptoms, such as nausea, vomiting, a disorder of
the sense of taste and depilation, as well as leukocytopenia
(< 2,000/μ l) were observed after radiation therapy. Howev-
er, the patient recovered in 2 months and returned to his
sedentary work. He has been followed for 3.5 years since
the operation and radiation therapy. He remains asympto-
matic and the MRI of his brain, spinal cord and cauda
equina have not showed any recurrence (Fig. 4). 
Discussion
It was reported that myxopapillary ependymoma is locat-
ed exclusively in the conus medullaris and cauda equina
region [1]. In the present case, the tumor was the multifocal
type at the L2-3 and L5-S1 levels. The multifocal type of
myxopapillary ependymoma is relatively rare. Sonneland et
al. [3] reported that both the film terminale and conus
medullaris were involved in 35% of patients. Hanbali et al.
[7] reported that 2 out of 26 patients had multifocal tumors.
Myxopapillary ependymoma is encapsulated in most cases
and a total resection can be performed safely in the majority
of patients. However, a total resection is sometimes difficult
in cases with involvement of the cauda equina or the film
terminale. In the present case, a subtotal resection for the
tumor was performed at the L5-S1 region because the tumor
was firmly attached to the S2 spinal nerve.
Approximately 90% of spinal cord ependymomas have a
benign pathology and are reported to be slow growing [1,3].
A favorable prognosis is expected when a total resection is
performed. However, a 50-70% recurrence rate of spinal
ependymoma has been reported after a subtotal resection [4-
6]. In addition, subarachnoid dissemination and external
metastasis has been observed occasionally [5,6,8]. There-
fore, it is necessary to pay close attention for possible tumor
recurrence in cases with a subtotal resection. In recent
years, a variety of cell proliferation markers have been used
to predict tumor recurrence and/or metastasis. The MIB-1
antibody was shown to be a reliable marker of cell prolifer-
ation. The MIB-1 antibody reacts with a nuclear antigen
expressed during the active phases of the cell cycle, includ-
ing G1, G2, S and M phases. MIB-1 LI has been used as an
operational marker of cell proliferation in a variety of
tumors. In myxopapillary ependymoma, Prayson [2] ana-
lyzed MIB-1 LI in 14 patients. His data suggested that the
MIB LI level was 0.9% on average, ranging from 0 to 5.5%
and MIB-1 IL was high in 2 cases with tumor recurrence.
Although he reported that MIB-1 LI is an unreliable predic-
tor of tumor recurrence, it should be noted that the patients
with a higher MIB-1 LI had tumor recurrence. Compared to
his data, the MIB-1 LI in the present case was extremely
high (9.1%), indicating a high likelihood of tumor growth,
recurrence and/or metastasis.
In the present case, cranio-spinal radiation therapy was
carried out after surgery because the patient had a multi-
focal type of myxopapillary ependymoma, high MIB-1 LI
and the tumor was removed in stages. In the series reported
by Hanbali et al. [7], one case of the multi-focal type had
tumor recurrence after surgery. Sonneland et al. [3], in their
analysis of 77 cases with myxopapillary ependymoma,
reported that total removal had a recurrence rate of 10%,
whereas those that were removed either piecemeal or subto-
tally had recurrence rates of 19%. Therefore, adjuvant radi-
ation therapy was recommended for cases without complete
resection [9]. Although there was no evidence of a dose-
response relationship between the amount of radiation and
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Fig. 4. Enhanced magnetic resonance imaging sagittal
view of the lumbar spine 3.5 year after surgery showing no
tumor recurrence.tumor progression, most institutes recommend radiation
doses in the range of 40-50 Gy. A total of 100 Gy radiation
was applied from the brain to the spinal cord and the cauda
equina. Each of the lesions received 30 Gy. In this case, it
was necessary to discontinue the radiation therapy due to
the unfavorable side effects, such as nausea, vomiting, dis-
order of sense of taste and depilation, and leukocytopenia
after radiation. Radiation myelopathy, which generally
occurs at doses > 55 Gy during the follow-up, should also
be considered.
The postoperative course of the present case was unevent-
ful during the follow-up. The patient had no tumor recur-
rence in the brain, spinal cord or the cauda equina. There
have been some cases of tumor recurrence, particularly in
cases with a subtotal resection [9]. Regarding chemothera-
py, one case report described the use of Imatinib for recur-
rent spinal ependymoma [10]. Chemotherapy was not added
because there is little data available on the benefit of
chemotherapy for spinal cord ependymomas. However, it
will be necessary to continue following this patient very
carefully.
In conclusion, we encountered a case of multi-focal
spinal ependymoma with high mitotic activity. A subtotal
resection was performed and cranio-spinal radiation was
added. The patient had an uneventful clinical course over
the 3.5 year follow-up period.
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